Fremont, United States
Verseon delivers on its ambitious slogan: Game-Changing Technology, Life-Changing Medicines by leveraging a proprietary, computer-driven drug discovery platform to innovate in the pharmaceutical industry. Established in 2002, this United States-based company pioneers in transforming drug design through advanced physics- and chemistry-based modeling. By focusing on creating novel molecular entities, Verseon aims to break away from traditional, slower pharmaceutical development cycles.
Boasting a diverse portfolio, Verseon is actively engaged in developing treatments for cardiovascular diseases, macular degeneration, oncology, metabolic disorders, and mutation-resistant antivirals. With over a dozen drug candidates in its pipeline, the company recently completed Phase 1 clinical trials for one candidate.
The company’s innovative pursuits are supported by a $3.24M Debt Financing investment received in April 2024. Competitively positioned within the Biotechnology, Health and Wellness, and Pharmaceutical industries, Verseon represents a compelling opportunity for investors seeking groundbreaking health tech advancements.
